XP-828L in the treatment of mild to moderate psoriasis: Randomized, double-blind, placebo-controlled study

Journal of Cutaneous Medicine and Surgery

Volumn 10, Issue 5, 2006, Pages 241-248

  Poulin, Yves ^a   Bissonnette, Robert ^a   Juneau, Christina ^a   Cantin, Kim ^a   Drouin, Rejean ^a   Poubelle, Patrice E ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPSORIASIS AGENT; NUTRACEUTICAL; PLACEBO; PROTEIN DERIVATIVE; UNCLASSIFIED DRUG; XP 828 L; XP 828L; DERMATOLOGICAL AGENT; MILK PROTEIN; XP-828L;

ADULT; ARTICLE; BODY SURFACE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; PHARYNGITIS; PRIORITY JOURNAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME; ANALYSIS OF VARIANCE; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; HOSPITALIZATION; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; ANALYSIS OF VARIANCE; CHI-SQUARE DISTRIBUTION; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MILK PROTEINS; PLACEBOS; PSORIASIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 34047161690     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.2310/7750.2006.00049     Document Type: Article

References (25)

1. Mayser P, Mrowietz U, Arenberger P, et al. Omega-3 fatty acid-based lipid infusion in patients with chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, multi-center trial. J Am Acad Dermatol 1998;38:539-47.
2. Veale DJ, Torley HI, Richards IM, et al. A double-blind placebo controlled trial of Efamol Marine on skin and joint symptoms of psoriatic arthritis. Br J Rheumatol 1994;33:954-8.
3. Soyland E, Funk J, Rajka G, et al. Effect of dietary supplementation with very-long-chain n-3 fatty acids in patients with psoriasis. N Engl J Med 1993;328:1812-6.
4. Gupta AK, Ellis CN, Tellner DC, et al. Double-blind, placebo-controlled study to evaluate the efficacy of fish oil and low-dose UVB in the treatment of psoriasis. Br J Dermatol 1989;120:801-7.
5. Gupta AK, Ellis CN, Goldfarb MT, et al. The role of fish oil in psoriasis. A randomized, double-blind, placebo-controlled study to evaluate the effect of fish oil and topical corticosteroid therapy in psoriasis. Int J Dermatol 1990;29:591-5.
6. Aattouri N, Gauthier SF, Santuré M, et al. Immunosupressive effect of a milk-derived extract [abstract]. Clin Invest Med 2004;27:1-4.
7. Poulin Y, Pouliot Y, Lamiot E, et al. Safety and efficacy of a milk-derived extract in the treatment of plaque psoriasis: an open-label study. J Cutan Med Surg 2005;9:271-5.
8. Marshall K. Therapeutic applications of whey protein. Altern Med Rev 2004;9:136-56.
9. Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol 2004;51:563-9.
10. Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis 2005;64:65-8.
11. Afuwape AO, Turner MW, Strobel S. Oral administration of bovine whey proteins to mice elicits opposing immunoregulatory responses and is adjuvant dependent. Clin Exp Immunol 2004;136: 40-8.
12. Kilara A, Panyam D. Peptides form milk proteins and their properties. Crit Rev Food Sci Nutr 2003;43:607-33.
13. Linden KG, Weinstein GD. Psoriasis: current perspectives with an emphasis on treatment. Am J Med 1999;107:595-605.
14. Bjorneboe A, Soyland E, Bjorneboe GE, et al. Effect of n-3 fatty acid supplement to patients with atopic dermatitis. J Intern Med Suppl 1989;731:233-6.
15. Christophers E. The immunopathology of psoriasis. Int Arch Allergy Immunol 1996;110:199-206.
16. Mueller W, Herrmann B. Cyclosporin A for psoriasis. N Engl J Med 1979;301:555.
17. Gottlieb SL, Gilleaudeau P, Johnson R, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1995;1: 442-7.
18. Ellis CN, Krueger GG, Alefacept Clinical Study Group. Treatment of chronic plaque psoriasis by selective targeting of memory effector to T lymphocytes. N Engl J Med 2001;345: 248-55.
19. Lebwohl M, Tyring SK, Hamilton TK, et al, Efalizumab Study Group. N Engl J Med 2003;349:2004-13.
20. Nicolas JF, Chamchick N, Thivolet J, et al. CD4 antibody treatment of severe psoriasis. Lancet 1991;338:321.
21. Krueger JG. The immunologic basis for treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002;46:1-23.
22. Gorelik L, Constant S, Flavell RA. Mechanism of transforming growth factor beta-induced inhibition of T helper type 1 differentiation. J Exp Med 2002;195:1499-505.
23. Beattie RM, Schiffrin EJ, Donnet-Hughes A, et al. Polymeric nutrition as the primary therapy in children with small bowel Crohn's disease. Aliment Pharmacol Ther 1994;8:609-15.
24. Oz HS, Ray M, Chen TS, McClain CJ. Efficacy of a transforming growth factor beta 2 containing nutritional support formula in a murine model of inflammatory bowel disease. J Am Coll Nutr 2004;23:220-6.
25. Schiffrin EJ, Yousfi ME, Faure M, et al. Milk casein-based diet containing TGF-beta controls the inflammatory reaction in the HLA-B27 transgenic rat. JPEN J Parenter Enteral Nutr 2005;29(4 Suppl):S141-8.